Picture EBD Group BIO-Europe Spring 2025 Milan to 14 Mar 650x100px

Product › Details

tafasitamab (MOR208 / XmAb5574)

	Next higher product group	antibody cancer drug
	Status	2020-08-01 registration start
	Organisation	MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
	Group	Novartis (Group)
	Organisation 2	Xencor Inc. (Nasdaq: XNCR)

Record changed: 2024-02-05

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for tafasitamab (MOR208 / XmAb5574)

[1] MorphoSys AG. (2/5/24). "Press Release: MorphoSys Enters into Business Combination Agreement to Be Acquired by Novartis for € 2.7 Billion Equity Value. Tafasitamab Sold to Incyte". Planegg....
[2] MorphoSys AG. (5/3/23). "Press Release: MorphoSys AG Reports First Quarter 2023 Financial Results". Planegg....
[3] MorphoSys AG. (8/31/22). "Press Release: MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters". Planegg....
[4] MorphoSys AG. (11/9/21). "Press Release: MorphoSys Announces Departure of Roland Wandeler". Planegg....
[5] MorphoSys AG. (8/26/21). "Press Release: MorphoSys and Incyte Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Plan...
[6] MorphoSys AG. (8/24/21). "Press Release: Health Canada Grants Marketing Authorization for Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma". Planegg....
[7] MorphoSys AG. (8/17/21). "Press Release: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China". Planegg....
[8] MorphoSys AG. (1/6/21). "Press Release: MorphoSys Appoints Sung Lee as Chief Financial Officer". Planegg....
[9] MorphoSys AG. (12/1/20). "Press Release: Thomas Biegi Joins MorphoSys as Head of Corporate Communications". Planegg....
[10] MorphoSys AG. (11/11/20). "Press Release: Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab". Monrovia, CA, Planegg & Wilmington, DE....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]